AbbVie Stock Slips as Sales Miss Expectations And Bigger Challenges Await.

Stock in AbbVie slipped after the drug company reported a higher profit than expected, while sales fell short.

The revenue shortfall may have reminded investors of a challenge


AbbVie


(ticker: ABBV) faces next year, when patent protection on its blockbuster arthritis drug Humira expires, allowing for the competition from generic versions. Humira, the best-selling drug in medical history, has achieved annual sales of $20.7 billion.